2378. Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy

BACKGROUND: Delafloxacin, a fluoroquinolone antibiotic with Gram-negative and Gram-positive activity including MRSA, was approved for treatment of ABSSSI. In a phase 3 ABSSSI trial, DLX was non-inferior to VAN/AZ in both objective and clinical response endpoints. Clinical signs and symptoms (S&S...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Pullman, John, O’Riordan, William, Lawrence, Laura, Quintas, Megan, Tseng, Carol, Cammarata, Sue K
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6255012/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.2031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados